Clinical trial • Phase III • Gastroenterology
ROPIVACAINE HYDROCHLORIDE for Inguinal hernia
Phase III trial of ROPIVACAINE HYDROCHLORIDE for Inguinal hernia.
Overview
- Trial Therapeutic Area
- Gastroenterology
- Trial Disease
- Inguinal hernia
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 06-08-2024
- First CTIS Authorization Date
- 05-11-2024
Trial design
Randomised, placebo control using nacl 0.9 solution (natriumchloride 0,9% fresenius kabi / nacl 0.9 solution). dose/schedule not specified in the provided documents. Phase III trial across 3 sites in Finland.
- Randomised
- Yes
- Comparator
- Placebo control using NaCl 0.9 solution (Natriumchloride 0,9% Fresenius Kabi / NaCl 0.9 solution). Dose/schedule not specified in the provided documents.
- Target Sample Size
- 200
Eligibility
Recruits 200 Vulnerable population not selected. Participants must be able to give written informed consent and have adequate Finnish language literacy; minors are excluded (age under 18 years)..
- Pregnancy Exclusion
- Pregnancy or breast-feeding, aim of becoming pregnant during the study,
- Vulnerable Population
- Vulnerable population not selected. Participants must be able to give written informed consent and have adequate Finnish language literacy; minors are excluded (age under 18 years).
Inclusion criteria
- {"criterion_text":"- Able to give a written informed consent\n- Aged 18 years or older at screening\n- Diagnosed with Inguinal hernia scheduled for open inguinal hernia surgery\n- Adequate Finnish language literacy\n- Unilateral surgery"}
Exclusion criteria
- {"criterion_text":"- Surgery that is planned to be performed under general or spinal anesthesia\n- Allergy or hypersensitivity to study medications or their ingredients\n- Pregnancy or breast-feeding, aim of becoming pregnant during the study,\n- Inability to provide written informed consent\n- Any significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk by participation in the study, or may influence the result of the study\n- A history of drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements\n- Prior or concurrent malignancy\n- Surgery that was not planned as day surgery\n- Bilateral surgery\n- Additional surgery to inguinal hernioplasty\n- Age under 18 years\n- Inability to give informed consent\n- Patient refusal\n- Chronic pain or prior opioid medication\n- Psychiatric disorder as defined by: medication used"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Equivalent morphine consumption in the perioperative period and after surgery, divided in: Intraoperative period, the immediate postoperative period, defined as the time between discharge from the operating room and discharge from the hospital and seven postoperative days","definition_or_measurement_approach":"Morphine consumption measured in defined time windows: intraoperative period; immediate postoperative period (time between discharge from the operating room and discharge from the hospital); and seven postoperative days."}
Secondary endpoints
- {"endpoint_text":"- postoperative pain, as defined by numerical rating scale (NRS), patient opinion of the efficacy of the pain treatment, postoperative nausea and vomiting (PONV), as defined as use of postoperative nausea medications, use of rescue analgesia, rescue hospitalization, intra- and postoperative durations, intraoperative anesthetic methods, analysis of patient flow and, anesthesiologic and surgical complications, depression and anxiety as measured by BDI and STAI queries","definition_or_measurement_approach":"Postoperative pain measured by numerical rating scale (NRS); PONV defined as use of postoperative nausea medications; depression and anxiety measured by BDI and STAI questionnaires; other items captured as stated (patient opinion, rescue analgesia use, rescue hospitalization, durations, complications, etc.)."}
Recruitment
- Planned Sample Size
- 200
- Recruitment Window Months
- 171
- Consent Approach
- Written informed consent required from each participant. A subject information sheet and informed consent form for adults (L1_SIS and ICF adults) are listed among documents. Participants must have adequate Finnish language literacy. Minors are excluded; no assent process described.
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 200
Finland
- Earliest CTIS Part Ii Submission Date
- 03-04-2024
- Latest Decision Or Authorization Date
- 06-11-2024
- Processing Time Days
- 217
- Number Of Sites
- 3
- Number Of Participants
- 200
Sites
- Site Name
- Tampere University Hospital
- Department Name
- Anestesia ja tehohoito
- Principal Investigator Name
- Maija-Liisa Kalliomäki
- Principal Investigator Email
- maija-liisa.kalliomaki@pirha.fi
- Contact Person Name
- Maija-Liisa Kalliomäki
- Contact Person Email
- maija-liisa.kalliomaki@pirha.fi
- Site Name
- Pirkanmaan hyvinvointialue (Valkeakoski)
- Department Name
- Anestesiologia ja tehohoito
- Principal Investigator Name
- Aki Lumme
- Principal Investigator Email
- aki.lumme@pirha.fi
- Contact Person Name
- Aki Lumme
- Contact Person Email
- aki.lumme@pirha.fi
- Site Name
- Pirkanmaan hyvinvointialue (Tampere Hatanpää)
- Department Name
- Anestesiologia ja tehohoito
- Principal Investigator Name
- Juha Virman
- Principal Investigator Email
- juha.virman@pirha.fi
- Contact Person Name
- Juha Virman
- Contact Person Email
- juha.virman@pirha.fi
Sponsor
Primary sponsor
- Full Name
- Pirkanmaan hyvinvointialue
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Finland
Investigational products
- Investigational Product Name
- Ropivacaine hydrochloride Kabi 7,5 mg/ml injekcinis tirpalas
- Active Substance
- ROPIVACAINE HYDROCHLORIDE
- Modality
- Small molecule
- Routes Of Administration
- INJECTION
- Route
- INJECTION
- Authorisation Status
- Authorised (marketingAuthorisationNumber: LT/1/22/5005/002)
- Maximum Dose
- 112.5 mg
- Investigational Product Name
- Natriumchloride 0,9% Fresenius Kabi oplossing voor infusie
- Active Substance
- SODIUM CHLORIDE
- Modality
- Small molecule
- Routes Of Administration
- INJECTION
- Route
- INJECTION
- Authorisation Status
- Authorised (marketingAuthorisationNumber: BE197127)
- Maximum Dose
- 30 ml
- Investigational Product Name
- NaCl 0.9 solution
- Modality
- Small molecule
Related trials
Other published trials that may interest you.